2022
DOI: 10.1016/j.ajoc.2022.101620
|View full text |Cite
|
Sign up to set email alerts
|

Myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccination: A case report

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
8
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 27 publications
0
8
0
Order By: Relevance
“…Another case report by Kang et al. (2022) also reported a 35‐year‐old male patient developing MG with ocular symptoms following the second dose of ChAdOx1 nCoV‐19 vaccination. Similarly, another case reported of ocular MG induced by the viral vector Oxford‐AstraZeneca coronavirus disease (COVID‐19) vaccine (Maher et al., 2022).…”
Section: Resultsmentioning
confidence: 88%
See 1 more Smart Citation
“…Another case report by Kang et al. (2022) also reported a 35‐year‐old male patient developing MG with ocular symptoms following the second dose of ChAdOx1 nCoV‐19 vaccination. Similarly, another case reported of ocular MG induced by the viral vector Oxford‐AstraZeneca coronavirus disease (COVID‐19) vaccine (Maher et al., 2022).…”
Section: Resultsmentioning
confidence: 88%
“…Another case report by Kang et al. ( 2022 ) also reported a 35‐year‐old male patient developing MG with ocular symptoms following the second dose of ChAdOx1 nCoV‐19 vaccination. Similarly, another case reported of ocular MG induced by the viral vector Oxford‐AstraZeneca coronavirus disease (COVID‐19) vaccine (Maher et al., 2022 ).Vaccines, particularly that with bovine, yeast, and chick antigens can induce subclinical autoimmunity as they synthesize antibodies that have the potential to cross‐react with AChR or MuSK protein, both causing myasthenia gravis (Arumugham, 2019 ).Infection, in this case with the SARS‐CoV‐2 virus, can then lead to a recall response of vaccine‐induced autoimmunity mediated by memory cells (Restivo et al., 2020 ).…”
Section: Resultsmentioning
confidence: 88%
“…New onset or exacerbation of ocular or generalized MG has been reported after BioNTech/Pfizer mRNA-vaccine BNT162b2, Moderna mRNA-1273, and AstraZeneca ChAdOx1 vaccines. ( 85 , 86 ) The age and gender of those patients mostly followed the demographic of the second peak of MG disease, which is commonly seen in men who are above 60 years of age( 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 ). Exacerbation of pre-existing MG post-vaccine is thought to be from 1-15%.…”
Section: Discussionmentioning
confidence: 99%
“…( 87 ) Ocular MG cases presented with intermittent fatigable ptosis and diplopia. ( 88 , 90 , 92 , 94 ) In some of the cases, associated symptoms occurred such as fatigue and weakness, myalgia, dysarthria, dysphagia, and head drop. ( 87 , 89 , 91 , 93 ) In 8 of the 11 patients acetylcholine receptors (AchR) antibodies was positive, but none were positive for anti-muscle-specific kinase (MuSK) antibodies.…”
Section: Discussionmentioning
confidence: 99%
“…presents detailed information of the included 18 case studies(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36) involving 48 patients. Twenty-eight of the 48 participants experienced the onset or flare of MG, and three of…”
mentioning
confidence: 99%